Volume 19 Supplement 1

Proceedings of the 1st International Conference of Collaborative Research Center 974: Liver Damage and Regeneration

Open Access

α5β1 integrins in hepatocytes act as receptors for bile acids with a (nor)ursodeoxycholane scaffold

  • Michele Bonus1,
  • Annika Sommerfeld2,
  • Dieter Häussinger2 and
  • Holger Gohlke1Email author
European Journal of Medical Research201419(Suppl 1):S13

DOI: 10.1186/2047-783X-19-S1-S13

Published: 19 June 2014

Ursodeoxycholic acid (UDCA) is a standard treatment in several cholestatic liver diseases (Figure 1A) [1]. In vivo, conjugation with taurine occurs rapidly and yields tauroursodeoxycholic acid (TUDC), which has been shown to promote choleresis by triggering the insertion of ATP-dependent transport proteins (e.g., the bile salt export pump (Bsep) and the multidrug resistance protein-2 (Mrp2)) into the canalicular membrane [2]. TUDC-induced recruitment of Bsep results from activation of focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI3 kinase), and c-Src, which leads to downstream activation of extracellular signal-regulated kinases (Erks) and p38 mitogen-activated protein kinase (p38MAPK). Upon hepatocyte swelling, either induced by exposure to a hypoosmotic environment or insulin, α5β1 integrins become activated and trigger similar signaling events towards choleresis. α5β1 Integrins may also become activated by a swelling-independent way as previously shown by exposing hepatocytes to pathophysiological concentrations of urea [3]. Both TUDC-induced and swelling-dependent signaling were abolished in the presence of an antagonistic, RGD-motif containing hexapeptide (GRGD SP).
Figure 1

(A) Scaffold and R-groups of the investigated bile acid derivatives. (B) Overlay of the starting structure of MD simulations of α5β1-integrin bound to TUDC (transparent) and the structure closest to the average as determined over the trajectory of 200 ns length (solid). For clarity, only the βA domain of α5β1-integrin is shown together with three Mg2+ ions (red spheres); TUDC was omitted. Three regions of characteristic conformational changes in the βA domain are visible: I) straightening of helix α1 (orange); II) T-junction formation between helices α1 and α7; III) tilting of helix α7 (blue).

These findings led us to hypothesize that α5β1 integrin will act as a receptor for TUDC in hepatocytes. We tested this hypothesis in a combined experimental and computational study [4]. Immunofluorescence staining on cryosections of isolated perfused rat liver (IPRL) revealed the active conformation of β1 integrin within 1 min after addition of TUDC at a concentration of 20 µM. Furthermore, phosphorylation of Erk-1 and -2 as well as activation of the epidermal growth factor receptor were induced by TUDC within the same time span. These effects were sensitive to inhibition by GRGD SP but insensitive to the presence of an inactive control peptide (GRADSP). As TUDC does not affect hepatocyte volume, which excludes that TUDC triggers integrin activation osmotically, these findings demonstrated that TUDC directly activates α5β1 integrins and triggers signaling events towards choleresis. While swelling-induced β1 integrin activation occurs primarily in the plasma membrane, TUDC-induced β1 integrin activation occurs primarily in the cytosol of hepatocytes. We demonstrated that the presence of the Na+/taurocholate cotransporting polypeptide (Ntcp) is required for the latter. The need to uptake and/or concentrate TUDC inside the hepatocyte for β1 integrin activation to occur may explain why TUDC primarily acts in the liver.

In order to provide insights at a molecular level as to how TUDC activates α5β1-integrin, a complex structure of a homology model of the ectodomain of α5β1-integrin and TUDC was generated by molecular docking and subsequently subjected to molecular dynamics (MD) simulations of 200 ns length [4]. These simulations revealed pronounced conformational changes in three regions of the βA domain of the integrin (Figure 1B): I) Helix α1 straightens and becomes continuous; II) this leads to a tighter packing between the top of helix α7 and the center of α1, which has been characterized as “T-junction formation” in an X-ray structure of integrin αIIbβ3 bound to a ligand as well as in computational studies of agonist-bound integrins; III) as a result, helix α7 moves downwards and outwards, which imposes a torque on the hybrid domain. The induced rotational motion of the hybrid domain is a prerequisite for the unbending of the integrin ectodomain, which, in turn, is required for integrin activation according to current models. Neither did MD simulations of the ectodomain of α5β1 integrin bound to GRGD SP nor to taurocholic acid (TC) (Figure 1A) reveal such conformational changes, in line with results from immunofluorescence staining of IPRL that did not reveal an appearance of the active conformation of β1-integrin upon addition of TC either. The bile acids glycochenodeoxycholic acid (GCDC), taurochenodeoxycholic acid (TCDC), or taurolithocholic acid 3-sulfate (TLCS) were likewise ineffective with respect to β1 integrin activation according to immunofluorescence staining. All these bile acids differ from TUDC with respect to the configuration and/or presence or absence of functional groups in the cholane moiety.

In contrast, the taurine conjugate (Tnor UDCA) of nor UDCA (Figure 1A), a C23 homolog of UDCA that lacks a methylene group in the sidechain, is moderately effective in exerting anticholestatic effects in experimental hepatocellular cholestatis [5]. Preliminary results from immunofluorescence staining of IPRL indicate that Tnor UDCA and nor UDCA can activate β1 integrins, with stronger effects observed with nor UDCA. Another sidechain modification occurs if glycine rather than taurine is conjugated with the bile acid in the terminal synthesis step. Preliminary results from immunofluorescence staining indicate that the glyco-conjugated UDCA (GUDC; Figure 1A) does not activate β1 integrins although GUDC can be transported by the Ntcp [6]. In order to investigate the bile acids’ modes of action at a molecular level, we subjected nor UDCA and GUDC bound to the ectodomain of α5β1 integrin to MD simulations, employing the same setup as for the simulations above. In addition, we also performed MD simulations of the complex of α5β1 integrin with the unconjugated UDCA as well as of a ligand-free structure of the α5β1 ectodomain for reference. Together with the above results for TUDC and TC-bound α5β1 integrin, these simulations reveal a significant correlation between characteristic conformational changes in the βA domain and the potential of the bile acid to activate β1 integrins as observed in immunofluorescence staining: I) the higher this potential (TUDC, nor UDCA), the less is helix α1 kinked and the more is helix α7 tilted with respect to the ligand-free structure; II) changes in the opposite direction are observed for the non-activating bile acids (TC, GUDC); III) the MD simulations reveal that changes of helix α1 towards an activated integrin state are more pronounced than those of helix α7. According to these preliminary results, we predict that UDCA does not activate β1 integrins because the conformational characteristics of helices α1 and α7 observed with this bile acid do not differ much from those of the ligand-free structure. Finally, the MD simulations suggest that the cholane scaffolds of TUDC and nor UDCA adopt different binding modes in the cleft between the propeller and βA domains of α5β1 integrin; yet, the activating effects of both bile acids is funneled through helix α1 and from there leads to allosteric changes in the βA domain that propagate towards the hybrid domain.

In summary, in a combined computational and experimental study, we showed that TUDC directly activates α5β1 integrins inside hepatocytes and induces conformational changes in the β1 subunit that lead to integrin activation and swelling-independent signaling towards choleresis. A bile acid with a nor ursodeoxycholane scaffold (nor UDCA) was shown to activate β1 integrins even without conjugation. In contrast, bile acids modified in the cholane scaffold (TC, TCDC, TLCS) or conjugated to glycine (GCDC, GUDC) were shown to be non-activating. This suggests a unique role of the (nor)ursodeoxycholane scaffold for direct interaction with and activation of α5β1 integrins in connection with no or a taurine conjugation.



This study was supported by the Deutsche Forschungsgemeinschaft through the Collaborative Research Centers SFB 575 (‘Experimental Hepatology’, Düsseldorf) and SFB 974 (‘Communication and Systems Relevance during Liver Damage and Regeneration’, Düsseldorf) and the Clinical Research Group KFO 217 (‘Hepatobiliary Transport in Health and Disease’, Düsseldorf), and by the initiative ‘Fit for Excellence’ at the Heinrich-Heine-University. The authors are grateful to the ‘Zentrum für Informations- und Medientechnologie’ (ZIM) at the Heinrich-Heine-University for computational support. We are grateful to Dr. Nadine Homeyer for fruitful discussions.

Authors’ Affiliations

Department of Mathematics and Natural Sciences, Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University
Clinic of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University


  1. Beuers U: Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nature Clin Pract Gastroenterol Hepatol 2006, 3: 318–328. 10.1038/ncpgasthep0521View ArticleGoogle Scholar
  2. Kurz AK, Graf D, Schmitt M, Vom Dahl S, Häussinger D: Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001, 121: 407–419. 10.1053/gast.2001.26262PubMedView ArticleGoogle Scholar
  3. Reinehr R, Gohlke H, Sommerfeld A, Vom Dahl S, Häussinger D: Activation of integrins by urea in perfused rat liver. J Biol Chem 2010, 285: 29348–29356. 10.1074/jbc.M110.155135PubMed CentralPubMedView ArticleGoogle Scholar
  4. Gohlke H, Schmitz B, Sommerfeld A, Reinehr R, Häussinger D: a5b1-Integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 2013, 57: 1117–1129. 10.1002/hep.25992PubMedView ArticleGoogle Scholar
  5. Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, Durchschein F, Thuringer A, Zollner G, Denk H, et al.: Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013, 58: 1201–1208. 10.1016/j.jhep.2013.01.026PubMed CentralPubMedView ArticleGoogle Scholar
  6. Maeda K, Kambara M, Tian Y, Hofmann AF, Sugiyama Y: Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Mol Pharm 2006, 3: 70–77. 10.1021/mp050063uPubMedView ArticleGoogle Scholar


© Bonus et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.